The seroepidemiology of B. pertussis infection in Catalonia, Spain

Epidemiology and Infection

Volumn 126, Issue 2, 2001, Pages 205-210

  Dominguez A ^a   Vidal, J ^b   Plans, P ^a   Salleras, L ^a  

^a GENERALITAT DE CATALUNYA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIUM ANTIBODY; FILAMENTOUS HEMAGGLUTININ ANTIBODY; PERTUSSIS TOXIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BORDETELLA PERTUSSIS; CHILD; COMMUNITY; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERTUSSIS; POPULATION; PREVALENCE; REVACCINATION; SCHOOL; SCHOOL CHILD; SEROEPIDEMIOLOGY; SPAIN; URBAN AREA;

ADHESINS, BACTERIAL; ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTININS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERTUSSIS TOXIN; RURAL POPULATION; SEROEPIDEMIOLOGIC STUDIES; SOCIAL CLASS; SPAIN; URBAN POPULATION; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 0343431421     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268801005325     Document Type: Article

References (26)

1. Edwards KM, Decker MD, Mortimer EA. Pertussis vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd edn. Philadelphia: WB Saunders Company, 1999: 293 344.
2. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA 1995; 273: 1044-6.
3. Neppelenbroek SE, de Melker HE, Conyn-Van Spaen Donck MAE. The incidence of pertussis in the Netherlands has remained high since an outbreak occurred in 1996. Eurosurveillance 1999; 4: 133-4.
4. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990; 161: 480-6.
5. Matter HC. Pertussis surveillance in Switzerland, 1992 to 1997 a large epidemic in 1994. What next? Eurosurveillance 1999; 4: 128 9.
6. Deville JG, Cherry JD, Christenson PD, et al. Frequency of Bordetella pertussis infections in adults. Clin Infect Dis 1995; 21: 639-42.
7. Olin P, Hallander HO Marked decline in pertussis vaccination in Sweden. Eurosurveillance 1999; 4: 128-9.
8. Social Class. Office of population census. London: OPSC, 1976.
9. Anuari Estadístic de Catalunya 1994-95. Barcelona: Institut d'Estadística de Catalunya, 1995.
10. Feinstein AR. Clinical epidemiology. The architecture of clinical research. Philadelphia: WB Saunders Company, 1985: 171-90.
11. Broome CV, Preblud SR, Bruner B, et al. Epidemiology of pertussis, Atlanta, 1977. J Pediatr 1981; 98: 362-7.
12. Sato H, Sato Y. Experience with diphtheria toxoidtetanus toxoid-acellular pertussis vaccine in Japan. Clin Infect Dis 1999; 28 (Suppl. 2): S124-30.
13. Keitel WA, Edwars KM. Pertussis in adolescents and adults: time to reimmunize? Semin Respir Infect 1995; 10: 51-7.
14. Cherry JD, Beer T, Chartrand SA, et al. Comparison of values of antibody to Bordetella pertussis antigens in young German and American men. Clin Infect Dis 1995; 20: 1271-4.
15. Rota MC, Ausiello CM, D'Amelio R, et al. Prevalence of markers of exposure to Bordetella pertussis among Italian young adults. Clin Infect Dis 1998; 26: 297-302.
16. Cattaneo LA, Reed GW, Haase DH, Wills MJ, Edwards KM. The seroepidemiology of Bordetella pertussis infections : a study of persons aged 1-65 years. J Infect Dis 1996; 173: 1256-9.
17. Hallender HO. Microbiological and serological diagnosis of pertussis. Clin Infect Dis 1999; 28 (Suppl. 2): S99-106.
18. Takayama N, Watanabe H, Fujita I, Minamitani M. Seroepidemiology of pertussis in the Japanese population. Med Microbiol Immunol 1989; 178: 1-8.
19. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. BMJ 1988; 296: 612-4.
20. Baron S, Njamkepo E, Grimpel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994; thirty years after a routine use of vaccine. Pediatr Infect Dis J 1998; 17:412-8.
21. Giuliano M, Mastrantonio P, Giammanco A, et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccine. Dev Biol Stand 1997; 89: 275-8.
22. Jenkinson D. Natural course of 500 consecutive cases of whooping cough: a general practice population study. BMJ 1995; 310: 299-302.
23. García-Corbeira P, Dal-Ré R, Aguilar L, Garcia de Lomas J. Seroepidemiology of Bordetella pertussis in the Spanish population. Vaccine 2000; 18: 2173-6.
24. Gardner P. Indications for acellular pertussis vaccine in adults: the case for selective, rather than universal, recommendations. Clin Infect Dis 1999; 28 (Suppl. 2): S131-5.
25. Orenstein WA. Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. Clin Infect Dis 1999; 28 (Suppl. 2): S147-50.
26. Cherry JD. Pertussis in the preantibiotic and prevaccine era with emphasis on adult pertussis. Clin Infect Dis 1999; 28 (Suppl. 2): S107-11.